Safety and Feasibility of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy With Calcium‐Containing Solutions: A Randomized Controlled Trial

Background

Calcium‐free (Ca‐free) solutions are theoretically the most ideal for regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT). However, the majority of medical centers in China had to make a compromise of using commercially available calcium‐containing (Ca‐containing) solutions instead of Ca‐free ones due to their scarcity. This study was designed to probe into the potential of Ca‐containing solution as a secure and efficient substitution for Ca‐free solutions.

Methods

In this prospective, randomized single‐center trial, 99 patients scheduled for CRRT were randomly assigned in a 1:1:1 ratio to one of three treatment groups: continuous veno‐venous hemodialysis Ca‐free dialysate (CVVHD Ca‐free) group, continuous veno‐venous hemodiafiltration calcium‐free dialysate (CVVHDF Ca‐free) group, and continuous veno‐venous hemodiafiltration Ca‐containing dialysate (CVVHDF Ca‐containing) group at cardiac intensive care unit (CICU). The primary endpoint was the incidence of metabolic complications. The secondary endpoints included premature termination of treatment, thrombus of filter, and bubble trap after the process.

Results

The incidence of citrate accumulation (18.2% vs. 12.1% vs. 21.2%) and metabolic alkalosis (12.1% vs. 0% vs. 9.1%) did not significantly differ among three groups (p > 0.05 for both). The incidence of premature termination was comparable among the groups (18.2% vs. 9.1% vs. 9.1%, p = 0.582). The thrombus level of the filter and bubble trap was similar in the three groups (p > 0.05 for all).

Conclusions

In RCA‐CRRT for CICU population, RCA‐CVVHDF with Ca‐containing solutions and traditional RCA with Ca‐free solutions had a comparable safety and feasibility.

Trial Registration: ChiCTR2100048238 in the Chinese Clinical Trial Registry.